Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation

Next Previous
Trial Profile

An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perillyl alcohol (Primary)
  • Indications Astrocytoma; Glioblastoma; Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NEONC Technologies

Most Recent Events

  • 19 Dec 2025 Planned End Date changed from 1 Dec 2025 to 1 Jun 2026.
  • 19 Dec 2025 Planned primary completion date changed from 1 Oct 2025 to 30 Mar 2026.
  • 11 Aug 2025 Planned End Date changed from 1 Jun 2024 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top